Data on chloroquine (CQ)-resistant Plasmodium vivax in Latin America is limited, even with
the current research efforts to sustain an efficient malaria control program in all these …

Background Chloroquine (CQ) and primaquine (PQ) are still the drugs of choice to treat
Plasmodium vivax malaria in many endemic areas, Brazil included. There is in vivo …

Background Chloroquine (CQ) over three days plus primaquine (PQ) for seven days is the
treatment of choice of infections by Plasmodium vivax in Bolivia, where 95% of the cases of …

Emerging Plasmodium vivax resistance to chloroquine (CQ) may undermine malaria
elimination efforts in South America. CQ-resistant P. vivax has been found in the major port …

The global emergence of Plasmodium vivax strains resistant to chloroquine (CQ) since the
late 1980s is complicating the current international efforts for malaria control and elimination …

We report for the first time a patient with malaria due to Plasmodium vivax who showed R2
resistance to chloroquine and R3 resistance to mefloquine in the Brazilian Amazon region …

Reports from several sites in South America suggest the presence of isolated cases of
chloroquine-resistant Plasmodium vivax malaria. To investigate the possibility of …

Plasmodium vivax resistance to chloroquine (CQ) is currently reported in almost all countries
where P. vivax is endemic. In Vietnam, despite a first report on P. vivax resistance to …

Seventy-nine adults with Plasmodium vivax malaria, from the Porto Velho area of Rondônia
(western Amazon region, Brazil), gave informed consent to participate in a blind, clinical …

In order to determine the frequency of therapeutic failures to chloroquine (CQ) in patients
with malaria due to either Plasmodium falciparum or P. vivax, and to explore the usefulness …